CareDx, Inc (CDNA) P/E Ratio History
Deep ValueTrading at -70.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2014–2025
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, CareDx, Inc (CDNA) trades at a price-to-earnings ratio of -70.8x, with a stock price of $28.31 and trailing twelve-month earnings per share of $-0.15.
The current P/E is 132% below its 5-year average of 220.1x. Over the past five years, CDNA's P/E has ranged from a low of 12.2x to a high of 958.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, CDNA trades at a 403% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, CDNA trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CDNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CDNA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CDNA P/E vs Peers
Molecular and Genetic Diagnostics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $29B | 35.2 | 8.32 | +171%Best | |
| $4B | 68.5 | - | +165% | |
| $2B | 47.4 | 7.07Best | +14% | |
| $192B | 29.1Lowest | 13.79 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CDNA Historical P/E Data (2014–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $14.54 | $1.19 | 12.2x | -94% |
| FY2025 Q2 | Jun 30 2025 | $19.54 | $1.02 | 19.2x | -91% |
| FY2025 Q1 | Mar 31 2025 | $17.75 | $1.09 | 16.3x | -93% |
| FY2024 Q4 | - | $21.41 | $0.90 | 23.8x | -89% |
| FY2015 Q1 | - | $5.54 | $0.01 | 423.3x | +92% |
| FY2014 Q4 | Dec 31 2014 | $7.25 | $0.08 | 87.2x | -60% |
| FY2014 Q3 | - | $7.00 | $0.01 | 958.9x | +336% |
Average P/E for displayed period: 220.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CDNA — Frequently Asked Questions
Quick answers to the most common questions about buying CDNA stock.
What is CDNA's P/E ratio?
CareDx, Inc (CDNA) trailing twelve-month P/E ratio is -70.8x, based on TTM diluted EPS of $-0.15. The 5-year average P/E is 220.1x and the historical range spans 12.2x to 958.9x.
Is CDNA stock overvalued or undervalued?
CDNA trades at -70.8x P/E, below its 5-year average of 220.1x. At the 0th percentile of its historical range (12.2x–958.9x), the stock is priced at a discount to its own history.
Is CDNA stock expensive?
No, CDNA is not expensive on a historical basis. The current P/E of -70.8x is below the 5-year average of 220.1x and sits at the 0th percentile of its valuation range.
What is CDNA's historical P/E range?
Over the past 5 years, CDNA's P/E ratio has ranged from 12.2x to 958.9x, with a median of 23.8x and an average of 220.1x. The current P/E of -70.8x places the stock at the 0th percentile of this range. Full historical data spans 2014–2025.
How does CDNA's P/E compare to the S&P 500?
CDNA trades at -70.8x P/E versus the S&P 500 median of 25.9x. The 373% discount to the market suggests lower growth expectations or perceived higher risk.
How does CDNA's valuation compare to Healthcare peers?
CareDx, Inc P/E of -70.8x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CDNA's PEG ratio?
CDNA PEG ratio is N/A, based on a P/E of -70.8x and EPS growth of -143.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CDNA's earnings yield?
CDNA earnings yield is N/A, the inverse of its -70.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.